Irene Ferrer

Dr. Irene Ferrer


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Clinical Therapeutics
Verified
Journal Article
Closed access
JZJon Zugazagoitia
Jon Zugazagoitia
CGCristiano Guedes
Cristiano Guedes
SPSantiago Ponce
Santiago Ponce
IFIrene Ferrer
Irene Ferrer
Sonia Molina PineloSonia Molina Pinelo
Sonia Molina Pinelo
LPLuis Paz-Ares
Luis Paz-Ares

31 May 2012 in Cancer Research
Verified
Journal Article
Open access
PDF file
MPMarta Palafox
Marta Palafox
IFIrene Ferrer
Irene Ferrer
PPPasquale Pellegrini
Pasquale Pellegrini
SVSergi Vila
Sergi Vila
SHSara Hernandez-Ortega
Sara Hernandez-Ortega
EGEva González-Suárez
Eva González-Suárez
Paracrine signaling through receptor activator of NF-κB (RANK) pathway mediates the expansion of mammary epithelia that occurs during pregnancy, and activation of RANK pathway promotes mammary tumorigenesis in mice. In this study we extend these previous data to human cells and show that the RANK pathway promotes the development of mammary stem cells and breast cancer. Overexpression of RANK (FL-RANK) in a panel of tumoral and normal human mammary cells induces the expression of breast cancer stem and basal/stem cell markers. High levels of RANK in untransformed MCF10A cells induce changes associated with both stemness and transformation, including mammary gland reconstitution, epithelial–mesenchymal transition (EMT), increased migration, and anchorage-independent growth. In addition, spheroids of RANK overexpressing MCF10A cells display disrupted acinar formation, impair growth arrest and polarization, and luminal filling. RANK overexpression in tumor cells with nonfunctional BRCA1 enhances invasiveness in acinar cultures and increases tumorigenesis and metastasis in immunodeficient mice. High levels of RANK were found in human primary breast adenocarcinomas that lack expression of the hormone receptors, estrogen and progesterone, and in tumors with high pathologic grade and proliferation index; high RANK/RANKL expression was significantly associated with metastatic tumors. Together, our findings show that RANK promotes tumor initiation, progression, and metastasis in human mammary epithelial cells by increasing the population of CD44+CD24− cells, inducing stemness and EMT. These results suggest that RANK expression in primary breast cancer associates with poor prognosis. Cancer Res; 72(11); 2879–88. ©2012 AACR.

1 October 2013 in Human Pathology
Verified
Journal Article
Closed access
CMCristina Mirantes
Cristina Mirantes
IEIñigo Espinosa
Iñigo Espinosa
IFIrene Ferrer
Irene Ferrer
XDXavier Dolcet
Xavier Dolcet
JPJaime Prat
Jaime Prat
XMXavier Matias-Guiu
Xavier Matias-Guiu

1 May 2017 in Stem Cell Reports
Verified
Journal Article
Open access
JGJorge Gómez-Miragaya
Jorge Gómez-Miragaya
MPMarta Palafox
Marta Palafox
LPLaia Paré
Laia Paré
GYGuillermo Yoldi
Guillermo Yoldi
IFIrene Ferrer
Irene Ferrer
EGEva González-Suárez
Eva González-Suárez
Taxanes are a mainstay of treatment for breast cancer, but resistance often develops followed by metastatic disease and mortality. Aiming to reveal the mechanisms underlying taxane resistance, we used breast cancer patient-derived orthoxenografts (PDX). Mimicking clinical behavior, triple-negative breast tumors (TNBCs) from PDX models were more sensitive to docetaxel than luminal tumors, but they progressively acquired resistance upon continuous drug administration. Mechanistically, we found that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands during the acquisition of drug resistance. In the absence of the drug, the resistant CD49f+ population shrinks and taxane sensitivity is restored. We describe a transcriptional signature of resistance, predictive of recurrent disease after chemotherapy in TNBC. Together, these findings identify a CD49f+ population enriched in tumor-initiating ability and chemoresistance properties and evidence a drug holiday effect on the acquired resistance to docetaxel in triple-negative breast cancer.

1 April 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
AQAlvaro Quintanal-Villalonga
Alvaro Quintanal-Villalonga
Sonia Molina PineloSonia Molina Pinelo
Sonia Molina Pinelo
CCCristina Cirauqui
Cristina Cirauqui
LOLaura Ojeda-Márquez
Laura Ojeda-Márquez
ÁMÁngela Marrugal
Ángela Marrugal
LPLuis Paz-Ares
Luis Paz-Ares
There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma. We performed FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in inmortalized lung cell lines, and we also carried out surrogate and interaction assays. We performed monotherapy and combination EGFR/FGFR inhibitor sensitivity assays in vitro and in vivo in cell line- and patient-derived xenografts. We determined FGFR1 mRNA expression in a cohort of patients with anti-EGFR therapy-treated adenocarcinoma. We have reported a cooperative interaction between FGFR1 and EGFR in this context, resulting in increased EGFR activation and oncogenic signaling. We have provided in vitro and in vivo evidence indicating that FGFR1 expression increases tumorigenicity in cells with high EGFR activation in EGFR-mutated and EGFR wild-type models. At the clinical level, we have shown that high FGFR1 expression levels predict higher resistance to erlotinib or gefitinib in a cohort of patients with tyrosine kinase inhibitor-treated EGFR-mutated and EGFR wild-type lung adenocarcinoma. Dual EGFR and FGFR inhibition in FGFR1-overexpressing, EGFR-activated models shows synergistic effects on tumor growth in vitro and in cell line- and patient-derived xenografts, suggesting that patients with tumors bearing these characteristics may benefit from combined EGFR/FGFR inhibition. These results support the extended the use of EGFR inhibitors beyond monotherapy in the EGFR-mutated adenocarcinoma setting in combination with FGFR inhibitors for selected patients with increased FGFR1 overexpression and EGFR activation.

13 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Sonia Molina PineloSonia Molina Pinelo
Sonia Molina Pinelo
GGGabriel Gutierrez
Gabriel Gutierrez
MPMaria Dolores Pastor
Maria Dolores Pastor
MHMarta Hergueta
Marta Hergueta
GMGema Moreno-Bueno
Gema Moreno-Bueno
LPLuis Paz-Ares
Luis Paz-Ares
Squamous cell lung cancer (SCC) and adenocarcinoma are the most common histological subtypes of non-small cell lung cancer (NSCLC), and have been traditionally managed in the clinic as a single entity. Increasing evidence, however, illustrates the biological diversity of these two histological subgroups of lung cancer, and supports the need to improve our understanding of the molecular basis beyond the different phenotypes if we aim to develop more specific and individualized targeted therapy. The purpose of this study was to identify microRNA (miRNA)-dependent transcriptional regulation differences between SCC and adenocarcinoma histological lung cancer subtypes. In this work, paired miRNA (667 miRNAs by TaqMan Low Density Arrays (TLDA)) and mRNA profiling (Whole Genome 44 K array G112A, Agilent) was performed in tumor samples of 44 NSCLC patients. Nine miRNAs and 56 mRNAs were found to be differentially expressed in SCC versus adenocarcinoma samples. Eleven of these 56 mRNA were predicted as targets of the miRNAs identified to be differently expressed in these two histological conditions. Of them, 6 miRNAs (miR-149, miR-205, miR-375, miR-378, miR-422a and miR-708) and 9 target genes (CEACAM6, CGN, CLDN3, ABCC3, MLPH, ACSL5, TMEM45B, MUC1) were validated by quantitative PCR in an independent cohort of 41 lung cancer patients. Furthermore, the inverse correlation between mRNAs and microRNAs expression was also validated. These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.